| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/22/2004 | WO2004006961A1 Composition for cytocompatible, injectable, self-gelling chitosan solutions for encapsulating and delivering live cells or biologically active factors |
| 01/22/2004 | WO2004006959A1 Liquid dosage compositions of stable nanoparticulate active agents |
| 01/22/2004 | WO2004006956A1 Drugs for improving the prognosis of brain injury and a method of screening the same |
| 01/22/2004 | WO2004006944A1 Flower essence-containing medicaments |
| 01/22/2004 | WO2004006940A1 Medicinal composition for drug-induced neuropathy |
| 01/22/2004 | WO2004006939A1 Blocking inflammation by inhibiting st3-gal-vi activity |
| 01/22/2004 | WO2004006938A1 Method for reducing c-rective protein levels with non-antibacterial tetracycline formulations |
| 01/22/2004 | WO2004006937A2 Novel pharmaceutical compositions based on 5-alpha-reductase inhibitors and uses of same |
| 01/22/2004 | WO2004006936A1 Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy |
| 01/22/2004 | WO2004006935A1 Use of compounds that activate the sterol regulatory element binding protein (srebp) pathway |
| 01/22/2004 | WO2004006934A2 1,4,7,10-tetraazacyclododecanes as modulators of the guanine-binding protein for treating tumours |
| 01/22/2004 | WO2004006933A2 Crystal forms of olanzapine and processes for their preparation |
| 01/22/2004 | WO2004006932A1 Broad-spectrum anti-emetic compositions and associated methods |
| 01/22/2004 | WO2004006931A2 Pharmaceutical compostions comprising an allosteric carboxylic inhibitor of matrix metalloproteinase-13 and a selective inhibitor of cyclooxygenase-2 |
| 01/22/2004 | WO2004006930A1 Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
| 01/22/2004 | WO2004006929A1 Composition for nasal absorption |
| 01/22/2004 | WO2004006928A1 Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride |
| 01/22/2004 | WO2004006925A1 N-sulfonylpiperidines as metalloproteinase inhibitors (tace) |
| 01/22/2004 | WO2004006921A1 Process for producing coated preparation |
| 01/22/2004 | WO2004006920A1 Topical treatment of skin diseases |
| 01/22/2004 | WO2004006919A1 Medicinal composition for mitigating blood lipid or lowering blood homocystein |
| 01/22/2004 | WO2004006918A1 Phenylalanine enamide derivatives containing a spiro`3.5!non-1-ene ring for use as integrin inhibitors |
| 01/22/2004 | WO2004006917A1 Dispersible tablets for oral administration |
| 01/22/2004 | WO2004006915A1 Angiotensin non-at1 receptor stimulating agents for brain ischemia protection and for acute stroke treatment |
| 01/22/2004 | WO2004006914A1 Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
| 01/22/2004 | WO2004006913A1 Combination of an allosteric inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
| 01/22/2004 | WO2004006912A2 Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib |
| 01/22/2004 | WO2004006911A2 Compositions intended for the treatment of peripheral neuropathies, preparation thereof and uses of same |
| 01/22/2004 | WO2004006910A1 Lipid oxidation products for inhibiting inflammation |
| 01/22/2004 | WO2004006909A1 Combination of chemotherapeutic drugs for increasing antitumor activity |
| 01/22/2004 | WO2004006908A1 Remedies for pigmentation |
| 01/22/2004 | WO2004006907A1 Modified amino acid for the inhibition of platelet aggregation |
| 01/22/2004 | WO2004006906A2 Methods for the treatment of neoplasms |
| 01/22/2004 | WO2004006905A1 Modafinil pharmaceutical compositions |
| 01/22/2004 | WO2004006904A1 Oral controlled-release dosage forms containing acetaminophen |
| 01/22/2004 | WO2004006903A1 The treatment of emesis |
| 01/22/2004 | WO2004006902A1 Combination of an allosteric inhibitor or matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib |
| 01/22/2004 | WO2004006901A1 Gastrointestinal compositions comprising gaba derivatives |
| 01/22/2004 | WO2004006900A2 Sulphydryl compounds in combination with sulphone or sulphnamide conpounds for use in microbial inflammatory diseases |
| 01/22/2004 | WO2004006899A1 Combination of an ibat inhibitor and a metal salt for the treatment of diarrhoea |
| 01/22/2004 | WO2004006895A1 Lasofoxifene tablet and its coating |
| 01/22/2004 | WO2004006894A1 Medicaments containing vardenafil hydrochloride trihydrate |
| 01/22/2004 | WO2004006892A1 Implantable orthopedic surgical devices with controlled release antimicrobial component |
| 01/22/2004 | WO2004006890A1 Non-polymeric lipophilic pharmaceutical implant compositions for intraocular use |
| 01/22/2004 | WO2004006889A1 Bioerodible film for ophthalmic drug delivery |
| 01/22/2004 | WO2004006888A2 Stabilization of the profile of release of active substances from a formulation |
| 01/22/2004 | WO2004006886A2 Injectable depot formulation comprising crystals of iloperidone |
| 01/22/2004 | WO2004006885A2 Systems for releasing active ingredients, based on biodegradable or biocompatible polymers with a shape memory effect |
| 01/22/2004 | WO2004006884A2 Process for providing a stable crystalline form of salbutamol |
| 01/22/2004 | WO2004006867A2 2-amino-9-[(2-hydroxymethyl) cyclopropylidenemethyl] purine antiviral agents |
| 01/22/2004 | WO2004006866A2 Antifungal therapeutic targets |
| 01/22/2004 | WO2004006865A2 Compounds, compositions, and methods |
| 01/22/2004 | WO2004006863A2 Therapeutic devices for patterned cell growth |
| 01/22/2004 | WO2004006858A2 Compounds, compositions, and methods employing same |
| 01/22/2004 | WO2004006856A2 Iron sequestration or elimination to reduce neurodegeneration or parkinsons disease progression |
| 01/22/2004 | WO2004006853A2 Treatment and prophylaxis with 4-1bb-binding agents |
| 01/22/2004 | WO2004006852A2 Method for selectively inhibiting fungal growth |
| 01/22/2004 | WO2004006850A2 3, 10, AND 12a SUBSTITUTED TETRACYCLINE COMPOUNDS |
| 01/22/2004 | WO2004006849A2 Combinations of drugs for the treatment of neoplasms |
| 01/22/2004 | WO2004006848A2 Combination therapies with ftc for the treatment of hepatitis b virus infection |
| 01/22/2004 | WO2004006843A2 Combination therapies with l-fmau for the treatment of hepatitis b virus infection |
| 01/22/2004 | WO2004006842A2 Combinations of drugs for the treatment of neoplasms |
| 01/22/2004 | WO2004006841A2 Use of amino acids for treatment of various conditions |
| 01/22/2004 | WO2004006836A2 Treatment of neuropathic pain with 6h-pyrrolo[3,4-d]pyridazine compounds |
| 01/22/2004 | WO2004006835A2 Novel compounds, pharmaceutical compositions containing same, and methods of use for same |
| 01/22/2004 | WO2004006834A2 Leflunomide analogs for treating rheumatoid arthritis |
| 01/22/2004 | WO2004006833A2 Bowel cleansing composition |
| 01/22/2004 | WO2004006832A2 Methods and compounds for reducing biofilm formation |
| 01/22/2004 | WO2004006801A2 Treatment for dry eye syndrome |
| 01/22/2004 | WO2004006692A1 Improved bulking agent compositions |
| 01/22/2004 | WO2003099231A3 Heteroaryl compounds which inhibit leukocyte adhesion mediated by alpha-4 integrins |
| 01/22/2004 | WO2003097107A3 Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier |
| 01/22/2004 | WO2003094837A3 Treatments with autologous fibroblast |
| 01/22/2004 | WO2003092649A3 Reduced formate poly(alkylene oxides) with secondary amines for reducing impurity formation |
| 01/22/2004 | WO2003092590A3 Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
| 01/22/2004 | WO2003090778A3 Dna vaccine combined with an inducer of tumor cell apoptosis |
| 01/22/2004 | WO2003087369A3 Ribozyme capable of specifically cleaving mmp-13 |
| 01/22/2004 | WO2003082813A3 Improvements in pharmaceutical compositions |
| 01/22/2004 | WO2003080545A3 Substituted phenylacetic acids |
| 01/22/2004 | WO2003078595A3 Immunostimulatory double stranded rna and methods of inducing, enhancing or modulating the immune response |
| 01/22/2004 | WO2003072802A3 Carboxyfullerenes and methods of use thereof |
| 01/22/2004 | WO2003072030A3 Methods for preventing or treating cardiac arrhythmia |
| 01/22/2004 | WO2003072022A3 Oral trimethobenzamide formulations and methods |
| 01/22/2004 | WO2003066087A3 Kinases involved in the regulation of energy homeostasis |
| 01/22/2004 | WO2003066086A3 Proteins involved in the regulation of energy homeostatis |
| 01/22/2004 | WO2003066022A3 Stable pharmaceutical composition useful for treating gastrointestinal disorders |
| 01/22/2004 | WO2003064383A3 Phosphorus-containing compounds & uses thereof |
| 01/22/2004 | WO2003063789A3 L-carnitine for treatment of hearing loss |
| 01/22/2004 | WO2003061402A3 Reduction of renal damage in companion animals |
| 01/22/2004 | WO2003059911A3 4-OXO-4, 7-DIHYDROFURO[2,3-b]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS |
| 01/22/2004 | WO2003059144A3 Method and process for producing youthful-appearing, small-pored, and smooth skin |
| 01/22/2004 | WO2003057140A3 Composition and methods for treatment of neurological disorders |
| 01/22/2004 | WO2003055462A3 Composition comprising at least an alkanolamide for inhibiting langerhans cell migration, and uses thereof |
| 01/22/2004 | WO2003055447A3 Heterocyclic acridone inhibitors of impdh enzyme |
| 01/22/2004 | WO2003051979A3 Compositions and methods for high sorption of skin materials and delivery of sulfur |
| 01/22/2004 | WO2003050248A3 Adenine nucleotide-binding protein-directed probes and methods of their synthesis and use |
| 01/22/2004 | WO2003049690A3 Hiv integrase inhibitors |
| 01/22/2004 | WO2003048205A3 Novel proteins with il-6 inhibiting activity |
| 01/22/2004 | WO2003045431A3 Methods for treating cancer using a combination of a tumor-derived dendritic cell inhibitory factor antagonist and a toll-like receptor agonist |
| 01/22/2004 | WO2003045399A3 Composition based on diosgenin ester for topical use |